— New facility will include comprehensive mammalian process development and manufacturing capabilities
/PRNewswire/ — AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other types of therapeutic proteins.
AGC Biologics currently provides mammalian protein process development and manufacturing services from its facilities in Bothell, WA; Berkeley, CA; and Copenhagen, Denmark, as well as microbial process development and manufacturing services from its facilities in Heidelberg, Germany; Copenhagen, Denmark; and Chiba, Japan. The Company will leverage its extensive experience and expertise with mammalian production systems to rapidly establish these services at its site in Japan.
“This is a key investment for AGC Biologics that will expand our capabilities and reinforce our leadership position in the Japanese CDMO marketplace,” said Gustavo Mahler, PhD, Chief Executive Officer of AGC Biologics. “Our new mammalian capabilities will represent a unique and convenient option for companies in Asia seeking mammalian production services nearby and for US and European companies seeking production in Asia.”
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization, with a strong commitment to deliver the highest standard of service to our clients. AGC Biologics has an extensive network of cGMP facilities in the US, Europe and Asia. We offer deep industry expertise, innovative solutions and technologies, and customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial, for mammalian and microbial. We forge exceptionally strong partnerships with our clients, and we never lose sight of our pledge to deliver reliable and compliant drug substance supply, on time. For more information, visit www.agcbio.com.
AGC Biologics Media Contact Information:
Robert J. Broeze, PhD
Chief Business Officer
Email: rbroeze@agcbio.com
SOURCE: AGC Biologics
